Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on February 1, 2018, to report its financial results for the fiscal year ended December 31, 2017. The filing includes unaudited condensed consolidated financial statements and updates to the Management's Discussion and Analysis (MD&A) and Risk Factors.
Key Financial Metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Total Revenue | $93.5 million | $90.7 million |
| Product, Service & Other Revenue | $93.5 million | $78.6 million |
| Gross Profit | $34.7 million | $44.2 million |
| Gross Margin | 37% | 49% |
| Operating Expenses | $124.4 million | $115.4 million |
| Net Loss | $92.2 million | $74.4 million |
| Cash, Cash Equivalents & Investments | $62.9 million | $72.0 million |
Operating expenses included non-cash stock-based compensation of $18.0 million in 2017 and $17.4 million in 2016.
Material Changes Versus Prior Period
- Revenue Composition: Total revenue increased slightly year-over-year, but the composition changed significantly. 2016 included $12.1 million of contractual revenue, whereas 2017 included none. Excluding this one-time item, product and service revenue grew 19%.
- Gross Margin Decline: Reported gross margin dropped from 49% to 37%. The 2016 margin was inflated by the $12.1 million of contractual revenue which carried a 100% gross margin. On an adjusted basis (excluding the 2016 contractual revenue), the margin declined from 41% to 37%, primarily attributed to an increase in costs.
- Widening Loss: Net loss increased by approximately 24% to $92.2 million, driven by higher operating expenses and lower gross profit.
- Liquidity: Cash, cash equivalents, and investments decreased by $9.1 million to $62.9 million.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Company's future performance, which are subject to risks and uncertainties. Management notes that actual results could differ materially from anticipated results due to risks described in the most recent Form 10-K. The Company has updated its disclosure regarding Business and Risk Factors (Exhibit 99.2) but does not provide specific numerical guidance or outlook for future periods in this text. The Company assumes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the details of the $12.1 million contractual revenue recognized in 2016 to understand the non-recurring nature of the prior year's margin.
- Review the specific drivers of the "increase in costs" cited as the primary reason for the adjusted gross margin decline.
- Examine the updated Risk Factors in Exhibit 99.2 for new or heightened operational risks.
- Assess the burn rate relative to the $62.9 million cash balance to determine runway without additional financing.
- Confirm the breakdown of operating expenses to evaluate the sustainability of the $124.4 million spend level.